Question normal

With the widespread use of the direct anticoagulants, and the emergence of reversal agents such as idarucizumab, what is current best approach to managing bleeding on direct anticoagulants? I understand idarucizumab is still quite costly, is specific to dabigatran. Is there a situation where a reversal agent would be your first choice of treatment? What would be your approach?